1. Elit L M, Gafni A, Levine M N. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective. Journal of Clinical Oncology 1997;15(2):632-639.
2. McGuire W, Neugut A I, Arikian S, Doyle J L, Dezii C M. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. Journal of Clinical Oncology 1997;15(2):640-645.(GOG III)
3. Covens A, Boucher S, Roche K, et al. Is paclitaxel and cisplatin a cost-effective first-line therapy for advanced ovarian carcinoma? Cancer 1996;77:2086-91.
4. Messori A, Trippoli S, Becagli P, Tendi E. Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma. Cancer 1996;78:2366-73.